The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

NCT02211690 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: dolutegravir 50 mg (one tablet daily)
DRUG: emtricitabine-tenofovir 300/200 mg (one tablet daily)

Sponsor

Andrew Carr

Collaborators

[object Object]